$14.00 Million in Sales Expected for Melinta Therapeutics Inc (NASDAQ:MLNT) This Quarter

Share on StockTwits

Wall Street analysts expect that Melinta Therapeutics Inc (NASDAQ:MLNT) will post $14.00 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Melinta Therapeutics’ earnings. The highest sales estimate is $14.40 million and the lowest is $13.60 million. Melinta Therapeutics posted sales of $12.02 million during the same quarter last year, which indicates a positive year over year growth rate of 16.5%. The business is expected to report its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Melinta Therapeutics will report full year sales of $62.34 million for the current year, with estimates ranging from $54.93 million to $73.00 million. For the next financial year, analysts anticipate that the firm will post sales of $91.44 million, with estimates ranging from $79.51 million to $102.80 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Melinta Therapeutics.

Melinta Therapeutics (NASDAQ:MLNT) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($2.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.72) by $0.38. Melinta Therapeutics had a negative net margin of 161.27% and a negative return on equity of 61.13%. The company had revenue of $14.08 million during the quarter, compared to the consensus estimate of $16.83 million.

Several brokerages have recently issued reports on MLNT. Cantor Fitzgerald set a $15.00 price target on shares of Melinta Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 19th. Gabelli reissued a “sell” rating on shares of Melinta Therapeutics in a report on Thursday, June 20th. Zacks Investment Research downgraded shares of Melinta Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 27th. WBB Securities downgraded shares of Melinta Therapeutics from a “speculative buy” rating to a “hold” rating in a report on Thursday, June 20th. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target (down previously from $45.00) on shares of Melinta Therapeutics in a report on Thursday, June 20th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Shares of MLNT traded down $0.24 during midday trading on Friday, hitting $5.72. 1,607,056 shares of the stock traded hands, compared to its average volume of 5,994,736. Melinta Therapeutics has a 1-year low of $1.62 and a 1-year high of $35.00. The company has a market capitalization of $69.38 million, a price-to-earnings ratio of -0.32 and a beta of 2.64. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.40 and a quick ratio of 1.06. The company’s 50 day simple moving average is $3.03.

A number of hedge funds have recently bought and sold shares of MLNT. Rhumbline Advisers lifted its holdings in Melinta Therapeutics by 59.1% in the fourth quarter. Rhumbline Advisers now owns 44,129 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 16,400 shares during the period. Algert Global LLC acquired a new stake in Melinta Therapeutics in the first quarter worth about $39,000. Condor Capital Management acquired a new stake in Melinta Therapeutics in the fourth quarter worth about $55,000. Bank of New York Mellon Corp lifted its holdings in Melinta Therapeutics by 11.3% in the fourth quarter. Bank of New York Mellon Corp now owns 142,938 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 14,567 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Melinta Therapeutics by 431.8% in the fourth quarter. Two Sigma Investments LP now owns 315,905 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 256,506 shares during the period. 26.81% of the stock is owned by institutional investors and hedge funds.

Melinta Therapeutics Company Profile

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.

Recommended Story: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Melinta Therapeutics (MLNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tezos Trading Down 5.2% Over Last 7 Days
Tezos Trading Down 5.2% Over Last 7 Days
Paypex  Price Hits $0.0147
Paypex Price Hits $0.0147
STRAKS Market Cap Reaches $47,441.00
STRAKS Market Cap Reaches $47,441.00
Zacks: Brokerages Expect NuStar Energy L.P.  to Post $0.28 EPS
Zacks: Brokerages Expect NuStar Energy L.P. to Post $0.28 EPS
Prudential Financial Inc. Sells 24,694 Shares of INTL Fcstone Inc
Prudential Financial Inc. Sells 24,694 Shares of INTL Fcstone Inc
Wells Fargo & Company MN Acquires 36,099 Shares of SPDR S&P Retail ETF
Wells Fargo & Company MN Acquires 36,099 Shares of SPDR S&P Retail ETF


 
© 2006-2019 Zolmax.